New York Comprehensive Thalassemia Center
Found 5 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is C  [Clear All Filters]
2021
Boscoe AN, Yan Y, Hedgeman E, van Beers EJ, Al-Samkari H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S et al..  2021.  Comorbidities and complications in adults with pyruvate kinase deficiency.. Eur J Haematol. 106(4):484-492.
Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.
2020
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
2019
Weiss M, Jun MParisi, Sheth S.  2019.  Clinical and economic burden of regularly transfused adult patients with β-thalassemia in the United States: A retrospective cohort study using payer claims.. Am J Hematol. 94(5):E129-E132.
2018
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.